Comprehensive Analysis and Experimental Validation Reveal Elevated CLCN4 is a Promising Biomarker in Endometrial Cancer

Overview

Journal Aging (Albany NY)

Specialty Geriatrics

Date 2023 Sep 6

PMID 37671947

Authors

Chenyang Wang

Jing Li

Weina Liu

Shiya Li

Yi Zhang

Yanbin Jin

Jinquan Cui

Affiliations

Soon will be listed here.

Abstract

Several studies have reported the role of CLCN4 in tumor progression. However, its mechanism remains to be thoroughly studied. The objective of this study was to explore the potential pathogenic role of CLCN4 in endometrial carcinoma (UCEC) with a better understanding of the pathological mechanisms involved. The potential roles of CLCN4 in different tumors were explored based on The Cancer Genome Atlas (TCGA), the expression difference, mutation, survival, pathological stage, Immunity subtypes, Immune infiltration, tumor microenvironment (TME), tumor mutation burden (TMB), microsatellite instability (MSI), mismatch repair (MMR) related to CLCN4 were analyzed. Then, the expression, prognosis, mutation, and functional enrichment of CLCN4 in UCEC were analyzed. Immunohistochemical experiment was used to verify the expression of CLCN4 in endometrial cancer tissues and normal tissues. , we knocked down of CLCN4 in HEC-1-A cells and performed CCK8, WB, RT-PCR, wound-healing, transwell assays to further validation of the molecular function. Results revealed that high expression of CLCN4 was observed in 20 cancer types of TCGA. CLCN4 expression correlates with poor survival in MESO, BLCA, THCA, especially UCEC tumors. CLCN4 expression was significantly associated with CD4+ T-cell infiltration, especially CD4+ Th1-cell. Immunohistochemical experiment reveals that CLCN4 is high expressed in endometrial tumors, experiment reveals that knockdown of CLCN4 inhibits the cells proliferation, migration and invasion. Our study is the first to offer a comprehensive understanding of the oncogenic roles of CLCN4 on different tumors. CLCN4 may become a potential biomarker in UCEC.

Citing Articles

Tissue factor pathway inhibitor 2 as a serum biomarker for endometrial cancer: a single-center retrospective study.

Uomoto M, Ota Y, Suzuki Y, Yumori A, Narimatsu H, Koizume S BMC Cancer. 2024; 24(1):1058.

PMID: 39192208 PMC: 11351603. DOI: 10.1186/s12885-024-12827-0.

References

Lloyd S, Pearce S, Fisher S, Steinmeyer K, Schwappach B, Scheinman S . A common molecular basis for three inherited kidney stone diseases. Nature. 1996; 379(6564):445-9. DOI: 10.1038/379445a0. View

Suemori T, Susumu N, Iwata T, Banno K, Yamagami W, Hirasawa A . Intratumoral CD8+ Lymphocyte Infiltration as a Prognostic Factor and Its Relationship With Cyclooxygenase 2 Expression and Microsatellite Instability in Endometrial Cancer. Int J Gynecol Cancer. 2015; 25(7):1165-72. DOI: 10.1097/IGC.0000000000000482. View

Meiser B, Kaur R, Kirk J, Morrow A, Peate M, Wong W . Evaluation of implementation of risk management guidelines for carriers of pathogenic variants in mismatch repair genes: a nationwide audit of familial cancer clinics. Fam Cancer. 2020; 19(4):337-346. DOI: 10.1007/s10689-020-00183-4. View

Steinberg B, Huynh K, Brodovitch A, Jabs S, Stauber T, Jentsch T . A cation counterflux supports lysosomal acidification. J Cell Biol. 2010; 189(7):1171-86. PMC: 2894458. DOI: 10.1083/jcb.200911083. View

Zhou P, He N, Zhang J, Lin Z, Wang J, Yan L . Novel mutations and phenotypes of epilepsy-associated genes in epileptic encephalopathies. Genes Brain Behav. 2018; 17(8):e12456. DOI: 10.1111/gbb.12456. View

Cai S, Zhang Y, Han K, Ding Y . Expressions and clinical significance of COX-2, VEGF-C, and EFGR in endometrial carcinoma. Arch Gynecol Obstet. 2017; 296(1):93-98. DOI: 10.1007/s00404-017-4386-9. View

Montcourrier P, Mangeat P, Valembois C, Salazar G, Sahuquet A, Duperray C . Characterization of very acidic phagosomes in breast cancer cells and their association with invasion. J Cell Sci. 1994; 107 ( Pt 9):2381-91. DOI: 10.1242/jcs.107.9.2381. View

Poet M, Kornak U, Schweizer M, Zdebik A, Scheel O, Hoelter S . Lysosomal storage disease upon disruption of the neuronal chloride transport protein ClC-6. Proc Natl Acad Sci U S A. 2006; 103(37):13854-9. PMC: 1564226. DOI: 10.1073/pnas.0606137103. View

Gunther W, Luchow A, Cluzeaud F, Vandewalle A, Jentsch T . ClC-5, the chloride channel mutated in Dent's disease, colocalizes with the proton pump in endocytotically active kidney cells. Proc Natl Acad Sci U S A. 1998; 95(14):8075-80. PMC: 20931. DOI: 10.1073/pnas.95.14.8075. View

10.

Cui X, Zhang X, Liu M, Zhao C, Zhang N, Ren Y . A pan-cancer analysis of the oncogenic role of staphylococcal nuclease domain-containing protein 1 (SND1) in human tumors. Genomics. 2020; 112(6):3958-3967. DOI: 10.1016/j.ygeno.2020.06.044. View

11.

Clarke M, Devesa S, Harvey S, Wentzensen N . Hysterectomy-Corrected Uterine Corpus Cancer Incidence Trends and Differences in Relative Survival Reveal Racial Disparities and Rising Rates of Nonendometrioid Cancers. J Clin Oncol. 2019; 37(22):1895-1908. PMC: 6675596. DOI: 10.1200/JCO.19.00151. View

12.

Ishiguro T, Avila H, Lin S, Nakamura T, Yamamoto M, Boyd D . Gene trapping identifies chloride channel 4 as a novel inducer of colon cancer cell migration, invasion and metastases. Br J Cancer. 2010; 102(4):774-82. PMC: 2837579. DOI: 10.1038/sj.bjc.6605536. View

13.

Palmer E, Stuhlmann T, Weinert S, Haan E, Van Esch H, Holvoet M . De novo and inherited mutations in the X-linked gene CLCN4 are associated with syndromic intellectual disability and behavior and seizure disorders in males and females. Mol Psychiatry. 2016; 23(2):222-230. PMC: 5794876. DOI: 10.1038/mp.2016.135. View

14.

Soroceanu L, Manning Jr T, Sontheimer H . Modulation of glioma cell migration and invasion using Cl(-) and K(+) ion channel blockers. J Neurosci. 1999; 19(14):5942-54. PMC: 6783071. View

15.

Veeramah K, Johnstone L, Karafet T, Wolf D, Sprissler R, Salogiannis J . Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia. 2013; 54(7):1270-81. PMC: 3700577. DOI: 10.1111/epi.12201. View

16.

Dunn G, Bruce A, Ikeda H, Old L, Schreiber R . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3(11):991-8. DOI: 10.1038/ni1102-991. View

17.

Constantine G, Kessler G, Graham S, Goldstein S . Increased Incidence of Endometrial Cancer Following the Women's Health Initiative: An Assessment of Risk Factors. J Womens Health (Larchmt). 2018; 28(2):237-243. PMC: 6390656. DOI: 10.1089/jwh.2018.6956. View

18.

Melero I, Hervas-Stubbs S, Glennie M, Pardoll D, Chen L . Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007; 7(2):95-106. DOI: 10.1038/nrc2051. View

19.

Palucka K, Banchereau J, Mellman I . Designing vaccines based on biology of human dendritic cell subsets. Immunity. 2010; 33(4):464-78. PMC: 2975953. DOI: 10.1016/j.immuni.2010.10.007. View

20.

Morice P, Leary A, Creutzberg C, Abu-Rustum N, Darai E . Endometrial cancer. Lancet. 2015; 387(10023):1094-1108. DOI: 10.1016/S0140-6736(15)00130-0. View